Advertisement
U.S. markets close in 5 hours 32 minutes
  • S&P 500

    5,251.79
    +3.30 (+0.06%)
     
  • Dow 30

    39,755.93
    -4.15 (-0.01%)
     
  • Nasdaq

    16,393.02
    -6.50 (-0.04%)
     
  • Russell 2000

    2,120.25
    +5.90 (+0.28%)
     
  • Crude Oil

    82.35
    +1.00 (+1.23%)
     
  • Gold

    2,226.30
    +13.60 (+0.61%)
     
  • Silver

    24.70
    -0.05 (-0.19%)
     
  • EUR/USD

    1.0810
    -0.0020 (-0.18%)
     
  • 10-Yr Bond

    4.1980
    +0.0020 (+0.05%)
     
  • GBP/USD

    1.2639
    +0.0001 (+0.01%)
     
  • USD/JPY

    151.2850
    +0.0390 (+0.03%)
     
  • Bitcoin USD

    70,927.15
    +1,300.98 (+1.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,961.39
    +29.41 (+0.37%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference

Novan, Inc.
Novan, Inc.

Presentation with live webcast today, March 14th at 10:40 AM ET

DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference today, March 14, 2023 at 10:40 AM ET.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (novan.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Novan

Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. Novan has a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams, promoting products for plaque psoriasis, rosacea and acne. The U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum. The Company also has a pipeline of potential product candidates using its proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com


Advertisement